Ankylosing Spondylitis Learning Hub

Ankylosing spondylitis (AS) is an inflammatory arthritis that affects mainly the axial skeleton and the sacroiliac joints. As the disease progresses, there is a decrease in spinal mobility and physical function and an increase in disability. This can lead to substantial impairment in health-related quality of life. Recently, there have been a number of developments in AS, including an increased understanding of pathogenesis, assessment tools, and new therapies. This page provides education on the latest updates in managing patients with AS.

CME Activities

Polling Question

Related Resources

Downloadable Slide Kit

Diving Into Ankylosing Spondylitis: Pathogenesis, Treatment Guidelines, and Emerging Therapies

Download

Clinical Reference

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors.

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

New treatment paradigms in spondyloarthritis.

Measuring outcomes in ankylosing spondylitis: pearls and pitfalls.

Patient burden of axial spondyloarthritis.

Steering Committee

Atul A. Deodhar, MD

Steering Committee Chair

Professor of Medicine
Medical Director
Rheumatology Clinics and Immunology Infusion Center
Oregon Health & Science University
Portland, Oregon

Joerg Ermann, MD

Instructor in Medicine
Harvard Medical School
Brigham and Women's Hospital
Boston, Massachusetts

Marina N. Magrey, MD

Associate Professor of Medicine
Director, Rheumatology Fellowship and Arthritis Clinic
Case Western Reserve University School of Medicine at MetroHealth Medical Center
Cleveland, Ohio

Iris Zink, RN, BSN, MSN, ANP-BC, RN-BC

Nurse Practitioner Rheumatology Clinic (NPRC)
East Lansing, Michigan

John D. Reveille, MD

Division Director
Vice-Chair
Professor
Division of Rheumatology and Clinical Immunogenetics
University of Texas McGovern Medical School
Houston, Texas

Abhijeet S. Danve, MD

Assistant Professor of Clinical Medicine
Yale School of Medicine
Yale University
New Haven, Connecticut